Search

Your search keyword '"Harshman L"' showing total 230 results
Start Over Author "Harshman L"
230 results on '"Harshman L"'

1. 122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)

Author

Marron, T.U., primary, Naing, A., additional, Mantia, C., additional, Pennell, N., additional, Kim, H.R., additional, Villaruz, L., additional, El-Khoueiry, A.B., additional, Gerber, D.E., additional, Qin, A., additional, Kim, T-Y., additional, Altan, M., additional, Gandhi, L., additional, Appleman, L.J., additional, Yoon, S., additional, Hill, J., additional, Reichert, V., additional, Masia, R., additional, Harshman, L., additional, Patnaik, A., additional, and Morgensztern, D., additional

Published
2023
Full Text
View/download PDF

4. Renal outcome and plasma methylmalonic acid levels after isolated or combined liver or kidney transplantation in patients with methylmalonic acidemia: A multicenter analysis

Author

Dello Strologo, L, Spada, M, Vici, C, Atti, M, Rheault, M, Bjerre, A, Boyer, O, Calvo, P, D'Antiga, L, Harshman, L, Horster, F, Kolker, S, Jahnukainen, T, Knops, N, Krug, P, Krupka, K, Lee, A, Levtchenko, E, Marks, S, Stojanovic, J, Martelli, L, Mazariegos, G, Montini, G, Shenoy, M, Sidhu, S, Tangeras, T, Testa, S, Vijay, S, Wac, K, Wennberg, L, Concepcion, W, Garbade, S, Tonshoff, B, Dello Strologo L., Spada M., Vici C. D., Atti M. C. D., Rheault M., Bjerre A. K., Boyer O., Calvo P. L., D'Antiga L., Harshman L. A., Horster F., Kolker S., Jahnukainen T., Knops N., Krug P., Krupka K., Lee A., Levtchenko E., Marks S. D., Stojanovic J., Martelli L., Mazariegos G., Montini G., Shenoy M., Sidhu S., Tangeras T., Testa S., Vijay S., Wac K., Wennberg L., Concepcion W., Garbade S. F., Tonshoff B., Dello Strologo, L, Spada, M, Vici, C, Atti, M, Rheault, M, Bjerre, A, Boyer, O, Calvo, P, D'Antiga, L, Harshman, L, Horster, F, Kolker, S, Jahnukainen, T, Knops, N, Krug, P, Krupka, K, Lee, A, Levtchenko, E, Marks, S, Stojanovic, J, Martelli, L, Mazariegos, G, Montini, G, Shenoy, M, Sidhu, S, Tangeras, T, Testa, S, Vijay, S, Wac, K, Wennberg, L, Concepcion, W, Garbade, S, Tonshoff, B, Dello Strologo L., Spada M., Vici C. D., Atti M. C. D., Rheault M., Bjerre A. K., Boyer O., Calvo P. L., D'Antiga L., Harshman L. A., Horster F., Kolker S., Jahnukainen T., Knops N., Krug P., Krupka K., Lee A., Levtchenko E., Marks S. D., Stojanovic J., Martelli L., Mazariegos G., Montini G., Shenoy M., Sidhu S., Tangeras T., Testa S., Vijay S., Wac K., Wennberg L., Concepcion W., Garbade S. F., and Tonshoff B.

Published
2022

5. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Author

Bamias, A, Tzannis, K, Harshman, L C, Crabb, S J, Wong, Y -N, Kumar Pal, S, De Giorgi, U, Ladoire, S, Agarwal, N, Yu, E Y, Niegisch, G, Necchi, A, Sternberg, C N, Srinivas, S, Alva, A, Vaishampayan, U, Cerbone, L, Liontos, M, Rosenberg, J, Powles, T, Bellmunt, J, and Galsky, M D

Published
2018
Full Text
View/download PDF

9. Erratum: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (Annals of Oncology (2018) 29(2) (361–369), (S0923753419350392), (10.1093/annonc/mdx692))

Author

Bamias A., Tzannis K., Harshman L. C., Crabb S. J., Wong Y. -N., Kumar Pal S., De Giorgi U., Ladoire S., Agarwal N., Yu E. Y., Niegisch G., Necchi A., Sternberg C. N., Srinivas S., Alva A., Vaishampayan U., Cerbone L., Liontos M., Rosenberg J., Powles T., Bellmunt J., Galsky M. D., Bamias, A., Tzannis, K., Harshman, L. C., Crabb, S. J., Wong, Y. -N., Kumar Pal, S., De Giorgi, U., Ladoire, S., Agarwal, N., Yu, E. Y., Niegisch, G., Necchi, A., Sternberg, C. N., Srinivas, S., Alva, A., Vaishampayan, U., Cerbone, L., Liontos, M., Rosenberg, J., Powles, T., Bellmunt, J., and Galsky, M. D.

Abstract

Ann Oncol 2018; 29: 361–369 (doi: 10.1093/annonc/mdx692) In the original abstract, the sentence “About 1794 patients treated between 2000 and 2013 at 29 centers were analyzed. Median follow-up was 29.1 months.” Has been corrected to: “1794 patients treated between 2000 and 2013 at 29 centers were analyzed. Median follow-up was 29.1 months.” Table 2 has also been corrected as below (the last three lines of numbers have been moved down one line)

Published
2019

11. Abstracts of papers presented at the United States/Israel bard workshop on new targets for insect management in crop protection

Author

Masler, E. P., Kelly, T. J., Menn, J. J., Nachman, R. J., Holman, G. M., Zitnan, D., Takeda, M., Sauman, I., Sehnal, F., Segal, D., Altaratz, Michal, Richard, D. S., Gilbert, L. I., Applebaum, S. W., Shaaya, E., Lehmberg, E., Schooley, D. S., Ferenz, H. -J., Raina, A. K., Altstein, Miriam, Gazit, Y., Dunkelblum, E., Rafaeli, Ada, Hirsch, J., Soroker, Victoria, Kamensky, B., Shani, A., Ujvary, I., Dickens, J. C., Kamm, J. A., McDonough, L. M., Mazor, Michal, Kehat, M., Hefetz, A., Bar-Zakay, I., Peleg, B. A., Tumlinson, J. H., Casida, J. E., Cole, L. C., Deng, Y. L., Palmer, C. J., Hollingworth, R. M., Orr, Nailah, Orr, G. L., Eldefrawi, M. E., Eldefrawi, Amira T., Prestwich, G. D., Zlotkin, E., Eitan, M., Fowler, E., Moyer, M., Adams, M. E., Gordon, Dalia, Moskowitz, H., Handler, A. M., Gomez, S. P., O’Brochta, D. A., Raccah, B., Gal-On, A., Antignus, Y., Federici, B. A., Miller, L. K., Tomalski, M. D., O’Reilly, D. R., Eldridge, J. R., Gross, O., Tussen, P., Tal, J., Ward, V., Umetsu, T., Possee, R., McCutchen, B. F., Maeda, S., Ichinose, R., Harshman, L., Choudary, P., Beethan, J., Bonning, B., Hammock, B. D., Cohen, E., Ishaaya, I., Yamamoto, I., Yawetz, A., Zook-Rimon, Z., Dotan, A., Aharonson, N., Katan, J., Mingelgrin, U., Gerstl, Z., Muszkat, Lea, Bir, Lina, and Ascher, K. R. S.

Published
1991
Full Text
View/download PDF

14. A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.

Author

Luke J., Barve M., Stadler W., Russo P.L., Johnson M., Tripathi A., Pal S., Markman B., Marron T., Mobasher M., Miller R., Munneke B., Strahs D., Luciano G., Piccione E., Mahabhashyam S., Merchan J., Powderly J., Harshman L., Luke J., Barve M., Stadler W., Russo P.L., Johnson M., Tripathi A., Pal S., Markman B., Marron T., Mobasher M., Miller R., Munneke B., Strahs D., Luciano G., Piccione E., Mahabhashyam S., Merchan J., Powderly J., and Harshman L.

Abstract

Background CD73 expression is elevated in tumors and contributes to increasing levels of immunosuppressive adenosine in the tumor microenvironment. CD73 knockout mice exhibit reduced tumor growth and resistance to experimental metastasis. Inhibition of CD73 activity with an anti-CD73 antibody blocks adenosine production, shown to inhibit tumor growth in syngeneic models. Dual inhibition of CD73 and A2aR improves anti-tumor immune responses in mouse tumor models[1]. CPI-006 is a humanized IgG1 Fc gamma receptor binding-deficient anti-CD73 antibody that has a dual mechanism of action. It blocks CD73 catalytic activity and adenosine production. In addition, it has immunomodulatory activity on CD73 positive immune cells including B cells, T cells and antigen presenting cells. CPI-006 relieves adenosine-mediated immunosuppression in vitro as a single agent and in combination with ciforadenant[2]. CPI-006 is now being investigated in this Phase 1/1b multicenter, open label trial as single agent (SA), in combination with ciforadenant, an oral, small molecule, selective A2aR antagonist and in combination with pembrolizumab, an anti-PD1 indicated for the treatment of patients across a number of malignancies (NCT03454451). Methods Up to 462 subjects will be enrolled at approximately 35 sites in the US, Canada and Australia. Eligible patients with: non-small cell lung cancer (NSCLC), renal cell carcinoma cancer (RCC), urothelial bladder cancer, cervical cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostate cancer, head and neck cancer, triple-negative breast cancer, endometrial cancer, select sarcomas and non-Hodgkin lymphoma (NHL) who are relapsed, refractory or intolerant to 1 to 5 standard therapies; aged >= 18 yo; with adequate organ function and measurable disease. Study details is presented in Figure 1. The primary objective of the dose escalation is to assess safety/ tolerability, MTD or MDL of CPI-006 SA, in combination with ciforadenant and with pembr

Published
2019

16. Adherence to cisplatin-based regimens prescription in 'fit' patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis

Author

Bamias, A. Tzannis, K. Liontos, M. Crabb, S. J. and Harshman, L. De Giorgi, U. Bellmunt, J. Wong, Y-N. Pal, S. K. Ladoire, S. Sternberg, C. N. Powles, T. B. Yu, E. Y. Niegisch, G. Necchi, A. Vaishampayan, U. Agarwal, N. and Rosenberg, J. Investigators, R.

Published
2016

18. Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC)

Author

Necchi, A. Sonpavde, G. Lo Vullo, S. Bamias, A. Crabb, S. J. Harshman, L. Bellmunt, J. De Giorgi, U. Sternberg, C. Ladoire, S. Wong, Y-N. Yu, E. Y. Chowdhury, S. and Niegisch, G. Srinivas, S. Vaishampayan, U. Pal, S. K. and Rosenberg, J. Mariani, L. Galsky, M. D.

Published
2016

19. Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder

Author

Seisen, T., primary, Sun, M., additional, Lipsitz, S., additional, Abdollah, F., additional, Leow, J., additional, Menon, M., additional, Von Landenberg, N., additional, Gild, P., additional, Rouprêt, M., additional, Preston, M., additional, Harshman, L., additional, Kibel, A.S., additional, Nguyen, P., additional, Bellmunt, J., additional, Choueiri, T., additional, and Trinh, Q.-D., additional

Published
2017
Full Text
View/download PDF

21. Efficacité de la thérapie trimodale versus cystectomie radicale pour le traitement des tumeurs de vessie infiltrant le muscle localisées

Author

Seisen, T., primary, Sun, M., additional, Lipsitz, S., additional, Abdollah, F., additional, Leow, J., additional, Menon, M., additional, Preston, M., additional, Harshman, L., additional, Kibel, A., additional, Nguyen, P., additional, Bellmunt, J., additional, Choueiri, T., additional, and Trinh, Q., additional

Published
2016
Full Text
View/download PDF

22. Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC)

Author

Necchi, A., primary, Sonpavde, G., additional, Vullo, S.L.o., additional, Bamias, A., additional, Crabb, S.J., additional, Harshman, L., additional, Bellmunt, J., additional, De Giorgi, U., additional, Sternberg, C., additional, Ladoire, S., additional, Wong, Y.-N., additional, Yu, E.Y., additional, Chowdhury, S., additional, Niegisch, G., additional, Srinivas, S., additional, Vaishampayan, U., additional, Pal, S.K., additional, Rosenberg, J., additional, Mariani, L., additional, and Galsky, M.D., additional

Published
2016
Full Text
View/download PDF

23. Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis

Author

Bamias, A., primary, Tzannis, K., additional, Liontos, M., additional, Crabb, S.J., additional, Harshman, L., additional, De Giorgi, U., additional, Bellmunt, J., additional, Wong, Y.-N., additional, Pal, S.K., additional, Ladoire, S., additional, Sternberg, C.N., additional, Powles, T.B., additional, Yu, E.Y., additional, Niegisch, G., additional, Necchi, A., additional, Vaishampayan, U., additional, Agarwal, N., additional, Rosenberg, J., additional, and Investigators, R., additional

Published
2016
Full Text
View/download PDF

24. Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database

Author

Bamias, A., primary, Tzannis, K., additional, Liontos, M., additional, Harshman, L., additional, Crabb, S.J., additional, Wong, Y.-N., additional, Pal, S.K., additional, Powles, T.B., additional, Bellmunt, J., additional, De Giorgi, U., additional, Ladoire, S., additional, Agarwal, N., additional, Yu, E.Y., additional, Niegisch, G., additional, Sternberg, C.N., additional, Alva, A., additional, Srinivas, S., additional, Rosenberg, J., additional, and Investigators, R., additional

Published
2016
Full Text
View/download PDF

26. Corrections

Author

Masler, E. P., Kelly, T. J., Menn, J. J., Nachman, R. J., Holman, G. M., Zitnan, D., Takeda, M., Sauman, I., Sehnal, F., Segal, D., Altaratz, Michal, Richard, D. S., Gilbert, L. I., Applebaum, S. W., Shaaya, E., Lehmberg, E., Schooley, D. S., Ferenz, H. -J., Raina, A. K., Altstein, Miriam, Gazit, Y., Dunkelblum, E., Rafaeli, Ada, Hirsch, J., Soroker, Victoria, Kamensky, B., Shani, A., Ujvary, I., Dickens, J. C., Kamm, J. A., McDonough, L. M., Mazor, Michal, Kehat, M., Hefetz, A., Bar-Zakay, I., Peleg, B. A., Tumlinson, J. H., Casida, J. E., Cole, L. C., Deng, Y. L., Palmer, C. J., Hollingworth, R. M., Orr, Nailah, Orr, G. L., Eldefrawi, M. E., Eldefrawi, Amira T., Prestwich, G. D., Zlotkin, E., Eitan, M., Fowler, E., Moyer, M., Adams, M. E., Gordon, Dalia, Moskowitz, H., Handler, A. M., Gomez, S. P., O’Brochta, D. A., Raccah, B., Gal-On, A., Antignus, Y., Federici, B. A., Miller, L. K., Tomalski, M. D., O’Reilly, D. R., Eldridge, J. R., Gross, O., Tussen, P., Tal, J., Ward, V., Umetsu, T., Possee, R., McCutchen, B. F., Maeda, S., Ichinose, R., Harshman, L., Choudary, P., Beethan, J., Bonning, B., Hammock, B. D., Cohen, E., Ishaaya, I., Yamamoto, I., Yawetz, A., Zook-Rimon, Z., Dotan, A., Aharonson, N., Katan, J., Mingelgrin, U., Gerstl, Z., Muszkat, Lea, Bir, Lina, and Ascher, K. R. S.

Published
1991
Full Text
View/download PDF

27. 2607 Predicting venous thromboembolism (VTE) in metastatic urothelial tract tumors (UTT)

Author

Ramos, J., primary, Casey, M., additional, Bamias, A., additional, De Giorgi, U., additional, Bellmunt, J., additional, Harshman, L., additional, Ladoire, S., additional, Wong, Y.N., additional, Alva, A., additional, Necchi, A., additional, Recine, F., additional, Vaishampayan, U., additional, Niegisch, G., additional, Pal, S., additional, Crabb, S., additional, Golshayan, A., additional, Srinivas, S., additional, Rosenberg, J., additional, Galsky, M., additional, and Yu, E., additional

Published
2015
Full Text
View/download PDF

28. 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)

Author

Harshman, L., primary, Werner, L., additional, Wong, Y.N., additional, Yu, E., additional, Alva, A., additional, Crabb, S., additional, Powles, T., additional, Rosenberg, J., additional, Baniel, J., additional, Vaishampayan, U., additional, Berthold, D., additional, Ladoire, S., additional, Hussain, S., additional, Milowsky, M., additional, Agarwal, N., additional, Necchi, A., additional, Pal, S., additional, Recine, F., additional, Bellmunt, J., additional, and Galsky, M., additional

Published
2015
Full Text
View/download PDF

32. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Author

Ko, J J, primary, Choueiri, T K, additional, Rini, B I, additional, Lee, J-L, additional, Kroeger, N, additional, Srinivas, S, additional, Harshman, L C, additional, Knox, J J, additional, Bjarnason, G A, additional, MacKenzie, M J, additional, Wood, L, additional, Vaishampayan, U N, additional, Agarwal, N, additional, Pal, S K, additional, Tan, M-H, additional, Rha, S Y, additional, Yuasa, T, additional, Donskov, F, additional, Bamias, A, additional, and Heng, D Y C, additional

Published
2014
Full Text
View/download PDF

33. 797P - Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC)

Author

Necchi, A., Sonpavde, G., Vullo, S.L.o., Bamias, A., Crabb, S.J., Harshman, L., Bellmunt, J., De Giorgi, U., Sternberg, C., Ladoire, S., Wong, Y.-N., Yu, E.Y., Chowdhury, S., Niegisch, G., Srinivas, S., Vaishampayan, U., Pal, S.K., Rosenberg, J., Mariani, L., and Galsky, M.D.

Published
2016
Full Text
View/download PDF

34. 798P - Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database

Author

Bamias, A., Tzannis, K., Liontos, M., Harshman, L., Crabb, S.J., Wong, Y.-N., Pal, S.K., Powles, T.B., Bellmunt, J., De Giorgi, U., Ladoire, S., Agarwal, N., Yu, E.Y., Niegisch, G., Sternberg, C.N., Alva, A., Srinivas, S., Rosenberg, J., and Investigators, R.

Published
2016
Full Text
View/download PDF

35. 799P - Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis

Author

Bamias, A., Tzannis, K., Liontos, M., Crabb, S.J., Harshman, L., De Giorgi, U., Bellmunt, J., Wong, Y.-N., Pal, S.K., Ladoire, S., Sternberg, C.N., Powles, T.B., Yu, E.Y., Niegisch, G., Necchi, A., Vaishampayan, U., Agarwal, N., Rosenberg, J., and Investigators, R.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results